PE20130643A1 - Conjugados de anticuerpos multifuncionales - Google Patents

Conjugados de anticuerpos multifuncionales

Info

Publication number
PE20130643A1
PE20130643A1 PE2013000052A PE2013000052A PE20130643A1 PE 20130643 A1 PE20130643 A1 PE 20130643A1 PE 2013000052 A PE2013000052 A PE 2013000052A PE 2013000052 A PE2013000052 A PE 2013000052A PE 20130643 A1 PE20130643 A1 PE 20130643A1
Authority
PE
Peru
Prior art keywords
seq
antibody
conjugate
combivalizumab
covalently connected
Prior art date
Application number
PE2013000052A
Other languages
English (en)
Inventor
Abhijit Suresh Bhat
Curt William Bradshaw
Oliver Alexandre Laurent
Alice Lee
Richard Ryan Preston
David Tumelty
Lauren Diane Wood
Wei Hong Yu
Original Assignee
Covx Technologies Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Covx Technologies Ireland Ltd filed Critical Covx Technologies Ireland Ltd
Publication of PE20130643A1 publication Critical patent/PE20130643A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Abstract

SE REFIERE A UN CONJUGADO DEL ANTICUERPO MULTIFUNCIONAL (MAC) QUE COMPRENDE: (i) UN ANTICUERPO, O PORCION DE ANTIGENO DEL MISMO SELECCIONADO ENTE RITUXIMAB, CETIXIMAB, INFLIXIMAB, ADALIMUMAB, NATALIZUMAB, OMALIZUMAB, RANIBIZUMAB Y PALIVIZUMAB, QUE COMPRENDE AL MENOS UN FRAGMENTO DE UNA REGION KAPPA CONSTANTE DE CADENA LIGERA (CLk), QUE COMPRENDE AL MENOS LOS RESTOS 1 A 106 DE LA SEC ID N° 15, SEC ID N° 45, SEC ID N° 46 O SEC ID N° 47; (ii) UN ENGARCE QUE COMPRENDE LA FORMULA X-Y-Z, DONDE Z ES UN GRUPO QUE ESTA CONECTADO COVALENTEMENTE AL ANTICUERPO; Y ES UNA CADENA DE CONEXION BIOLOGICAMENTE COMPATIBLE LINEAL O RAMIFICADA; X ES UN GRUPO CONECTADO COVALENTEMENTE AL MENOS UN RESTO EFECTOR EL CUAL ES UNA PROTEINA O UN PEPTIDO DE UNION A ANG2 QUE COMPRENDE LA SECUENCIA SEC ID N° 27,28, 29 ENTRE OTROS. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION DEL CONJUGADO. DICHO CONJUGADO DE ANTICUERPO PROPORCIONA EL BENEFICIO DE LA TERAPIA BIFUNCIONAL EN EL TRATAMIENTO DE CANCER.
PE2013000052A 2010-07-12 2011-07-11 Conjugados de anticuerpos multifuncionales PE20130643A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36350710P 2010-07-12 2010-07-12

Publications (1)

Publication Number Publication Date
PE20130643A1 true PE20130643A1 (es) 2013-06-07

Family

ID=44630490

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000052A PE20130643A1 (es) 2010-07-12 2011-07-11 Conjugados de anticuerpos multifuncionales

Country Status (18)

Country Link
US (1) US8741291B2 (es)
EP (1) EP2593142B8 (es)
JP (2) JP5913307B2 (es)
KR (1) KR20130050966A (es)
CN (1) CN103096933A (es)
AR (1) AR082205A1 (es)
AU (1) AU2011277999A1 (es)
BR (1) BR112013000951A2 (es)
CA (1) CA2804185C (es)
CO (1) CO6670522A2 (es)
ES (1) ES2704223T3 (es)
MX (1) MX2013000491A (es)
PE (1) PE20130643A1 (es)
RU (1) RU2012157167A (es)
SG (1) SG186451A1 (es)
TW (1) TWI432213B (es)
WO (1) WO2012007896A1 (es)
ZA (1) ZA201300161B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013011172A2 (pt) * 2010-11-05 2017-06-06 Covx Tech Ireland Ltd compostos antidiabéticos
US9289512B2 (en) * 2011-06-21 2016-03-22 Immunogen, Inc. Maytansinoid derivatives with peptide linker and conjugates thereof
KR101733853B1 (ko) 2011-11-17 2017-05-08 화이자 인코포레이티드 세포독성 펩티드 및 그의 항체 약물 접합체
TW201341401A (zh) 2012-01-09 2013-10-16 Covx Technologies Ireland Ltd 突變抗體及其共軛
EP3632471A1 (en) 2012-10-11 2020-04-08 Daiichi Sankyo Company, Limited Antibody-drug conjugate
EP2910573B1 (en) 2012-10-19 2020-02-19 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
TW201431880A (zh) 2012-11-07 2014-08-16 Pfizer 抗切口３（ａｎｔｉ－ｎｏｔｃｈ３）抗體及抗體－藥物共軛體
RU2015116485A (ru) 2012-11-07 2016-12-27 Пфайзер Инк. Антитела к рецептору альфа 2 интерлейкина-13 и конъюгаты антитело-лекарственное средство
SG10201608703SA (en) 2012-11-08 2016-12-29 Eleven Biotherapeutics Inc Il-6 antagonists and uses thereof
JP6133431B2 (ja) 2012-11-24 2017-05-24 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用
CN105829543B (zh) * 2013-10-14 2021-06-01 西纳福克斯股份有限公司 糖基改造的抗体、抗体-缀合物及其制备方法
EP2935608A1 (en) * 2013-10-14 2015-10-28 SynAffix B.V. Modified glycoprotein, protein-conjugate and process for the preparation thereof
KR102535900B1 (ko) 2013-12-25 2023-05-26 다이이찌 산쿄 가부시키가이샤 항 trop2 항체-약물 컨쥬게이트
SG10201800210TA (en) * 2014-01-31 2018-02-27 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugate
US10464955B2 (en) 2014-02-28 2019-11-05 Hangzhou Dac Biotech Co., Ltd. Charged linkers and their uses for conjugation
KR102127623B1 (ko) 2014-04-10 2020-06-29 다이이찌 산쿄 가부시키가이샤 항her3 항체-약물 콘주게이트
ES2754348T3 (es) 2014-04-10 2020-04-17 Daiichi Sankyo Co Ltd Conjugado de (anticuerpo anti-HER2)-fármaco
MA51554A (fr) 2014-11-07 2020-11-18 Sesen Bio Inc Anticorps il-6 améliorés
CA2986486C (en) * 2015-05-20 2023-03-07 Immunwork Inc. Molecular constructs with targeting and effector elements and their applications
PE20180498A1 (es) * 2015-06-19 2018-03-09 Eisai Randd Man Co Ltd Inmunoglobulinas conjugadas en cys80
EP4180455A1 (en) 2015-06-29 2023-05-17 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
US9623118B2 (en) * 2015-09-01 2017-04-18 Immunwork Inc. Multi-arm linker constructs for treating pathological blood clots
CA2998740A1 (en) * 2015-09-17 2017-03-23 The Scripps Research Institute Dual variable domain immunoconjugates and uses thereof
UY36961A (es) * 2015-10-23 2017-05-31 Sorrento Therapeutics Inc Receptores celulares universales programables y métodos para usar los mismos
CN106729743B (zh) 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
CN107029244B (zh) * 2016-02-04 2021-04-27 浙江昭华生物医药有限公司 抗her2抗体-药物偶联物及其应用
WO2017139329A1 (en) 2016-02-09 2017-08-17 Alexander Krantz Site-selective functionalization of proteins using traceless affinity lables
WO2017147293A1 (en) * 2016-02-23 2017-08-31 Eleven Biotherapeutics, Inc. Il-6 antagonist formulations and uses thereof
WO2018009916A1 (en) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
AU2017377233A1 (en) 2016-12-12 2019-06-13 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
AU2018210081A1 (en) 2017-01-17 2019-08-08 Daiichi Sankyo Company, Limited Anti-GPR20 antibody and anti-GPR20 antibody-drug conjugate
US20190345186A1 (en) 2017-01-24 2019-11-14 Pfizer Inc. Calicheamicin deratives and antibody drug conjugates thereof
TW202330036A (zh) 2017-05-15 2023-08-01 日商第一三共股份有限公司 抗體-藥物結合物之製造方法
SG11202000997YA (en) 2017-08-31 2020-03-30 Daiichi Sankyo Co Ltd Improved method for producing antibody-drug conjugate
CN117838880A (zh) 2017-08-31 2024-04-09 第一三共株式会社 制备抗体-药物缀合物的新方法
WO2019090242A1 (en) * 2017-11-04 2019-05-09 Advanced Proteome Therapeutics Inc. Composition and method for modifying polypeptides
KR20200110362A (ko) 2018-01-12 2020-09-23 암젠 인크 Pac1 항체 및 이의 용도
DK3794042T3 (da) 2018-05-18 2024-04-15 Daiichi Sankyo Co Ltd Anti-muc1-exatecet-antistof-lægemiddelkonjugat
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US20210308273A1 (en) 2018-08-02 2021-10-07 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
KR20210081324A (ko) 2018-08-02 2021-07-01 다인 세라퓨틱스, 인크. 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
AU2020332026A1 (en) * 2019-08-19 2022-04-14 Shenyang Pharmaceutical University Antibody mutant and application thereof
WO2021046347A1 (en) 2019-09-04 2021-03-11 Bolt Biotherapeutics, Inc. Immunoconjugate synthesis method
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
WO2023077120A1 (en) * 2021-11-01 2023-05-04 Dyne Therapeutics, Inc. Muscle targeting complexes for treating dystrophinopathies
US11931421B2 (en) 2022-04-15 2024-03-19 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating myotonic dystrophy
WO2023201324A1 (en) * 2022-04-15 2023-10-19 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5733757A (en) 1995-12-15 1998-03-31 The Scripps Research Institute Aldolase catalytic antibody
CA2389250C (en) 1999-10-08 2010-07-20 The Scripps Research Institute Antibody catalysis of enantio- and diastereo-selective aldol reactions
HUP0302525A2 (hu) 2001-01-05 2003-10-28 Abgenix, Inc. Az inzulinszerű növekedési faktor I receptor elleni ellenanyagok
CN100560131C (zh) 2001-10-22 2009-11-18 斯克里普斯研究学院 抗体靶向化合物
US7217845B2 (en) * 2002-11-25 2007-05-15 Sun Bio, Inc. Bifunctional polyethylene glycol derivatives
US7579157B2 (en) 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
MXPA06001634A (es) 2003-08-13 2006-04-28 Pfizer Prod Inc Anticuerpos humanos modificados igf-1r.
JP5167473B2 (ja) 2005-03-03 2013-03-21 コヴェックス・テクノロジーズ・アイルランド・リミテッド 抗血管新生化合物
CN101611053B (zh) * 2006-11-10 2015-06-03 CovX科技爱尔兰有限公司 抗血管生成化合物
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
AU2008295506A1 (en) 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Anti-IGF-1R antibodies and uses thereof
SG10201605629VA (en) 2008-01-03 2016-08-30 Scripps Research Inst Antibody targeting through a modular recognition domain
US8293714B2 (en) 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies

Also Published As

Publication number Publication date
AU2011277999A1 (en) 2013-01-10
KR20130050966A (ko) 2013-05-16
EP2593142B1 (en) 2018-10-10
EP2593142B8 (en) 2018-12-26
BR112013000951A2 (pt) 2016-05-17
MX2013000491A (es) 2013-02-26
ES2704223T3 (es) 2019-03-15
CO6670522A2 (es) 2013-05-15
US20120201809A1 (en) 2012-08-09
JP5913307B2 (ja) 2016-04-27
CN103096933A (zh) 2013-05-08
EP2593142A1 (en) 2013-05-22
TW201216986A (en) 2012-05-01
JP2016094455A (ja) 2016-05-26
RU2012157167A (ru) 2014-08-20
US8741291B2 (en) 2014-06-03
JP2013534535A (ja) 2013-09-05
TWI432213B (zh) 2014-04-01
WO2012007896A1 (en) 2012-01-19
CA2804185A1 (en) 2012-01-19
SG186451A1 (en) 2013-01-30
AR082205A1 (es) 2012-11-21
ZA201300161B (en) 2013-09-25
JP6339995B2 (ja) 2018-06-06
CA2804185C (en) 2017-03-21

Similar Documents

Publication Publication Date Title
PE20130643A1 (es) Conjugados de anticuerpos multifuncionales
PE20060817A1 (es) Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina
PE20171512A1 (es) Anticuerpos anti-fap
CO6230999A2 (es) Anticuerpo anti-esclerostina
PE20190975A1 (es) Novela cd47 anticuerpos monoclonales y sus usos
ES2668645T3 (es) Conjugados de fármaco y anticuerpo (ADC) que se unen a proteínas 161P2F10B
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
PE20110306A1 (es) Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3)
RU2013138469A (ru) АНТИТЕЛА К ИНТЕРЛЕЙКИНУ-1α И СПОСОБЫ ПРИМЕНЕНИЯ
PE20140633A1 (es) Anticuerpos neutralizadores anti-ccl20
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
NZ627859A (en) Stabilized formulations containing anti-ang2 antibodies
ES2572177T3 (es) Anticuerpos neutralizantes anti-B7RP1 humanos
PE20140231A1 (es) Proteinas de union a antigeno contra proproteina converstasa subtilisina/kexina tipo 9 (pcsk9)
PE20040554A1 (es) Vacunas que comprenden proteinas de fusion
EA200870538A1 (ru) Лиофилизированные композиции анти-egfr антител
PE20120306A1 (es) Anticuerpos anti-egfr y vectores que los codifican
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
EA201401134A1 (ru) Hla-рестиктированные пептидоспецифические антигенсвязывающие белки
MY182680A (en) Antibody formulation and therapeutic regimens
PE20170903A1 (es) Conjugados de farmacos con anticuerpos anti-cdh6
NZ600768A (en) Human antibodies to human angiopoietin-like protein 4
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
RS54111B1 (en) ANTI-ALPHA 2 INTEGRIN ANTIBODIES AND THEIR USES
CY1114658T1 (el) Πρωτεϊνες δεσμευσης αντιγονου του αυξητικου παραγοντα τυπου επιδερμικου αυξητικου παραγοντα προσδεσης στην ηπαρινη

Legal Events

Date Code Title Description
FD Application declared void or lapsed